 
 
 
Date: November 14, 2025 
To  
The Secretary     
National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra-Kurla Complex, Bandra (East)  
Mumbai – 400 051  
  
Trading Symbol: DIVISLAB 
To  
The Secretary    
BSE Limited   
Phiroze Jeejeebhoy Towers,   
Dalal Street  
Mumbai – 400 001  
  
Scrip Code: 532488 
  
  
Dear Sir/ Madam,  
  
Sub: US-FDA Inspection of Company’s Unit-I  manufacturing facility at Lingojigudem 
Village, Yadadri Bhuvanagiri district, Telangana, India 
 
Ref: Regulation 30 of SEBI (Listing Ob ligations and Disclosure Requirements) 
Regulations, 2015 
 
This is to inform that the Company’s Unit-I  facility at Lingojigudem Village, Choutuppal 
Mandal, Yadadri Bhuvanagiri district, Telangana, has been inspected by the US Food and Drug 
Administration (US-FDA) from November 10, 20 25 to November 14, 2025. This inspection 
was a general cGMP inspection by the US-FDA. The insp ection has been concluded with          
no 483 observations. 
 
This is for your information and records. 
 
Thanking you, 
 
Yours faithfully, 
For Divi’s Laboratories Limited 
 
 
M. Satish Choudhury 
Company Secretary & Compliance Officer 
 
 
 
 
